-
Part 1 | Session 11 Plenary Session 5: Managing side effects of HF drugs
-
Part 1 | Session 12 Meet the expert: Sex differences in advanced heart failure
-
Part 1 | Session 13 Plenary Session 6: How to manage the obese patient with HF
-
Part 2 | Session 1 Plenary Session 7: New technologies to manage your patients
-
Part 2 | Session 3 Plenary Session 8: New technologies to treat your patients
-
Part 2 | Session 4 Plenary Session 9: Comparing European and US recent guidelines
-
Part 2 | Session 8 Plenary Session 11: Managing the HF patient with valvular heart disease
-
Part 2 | Session 10 Plenary Session 12: Managing the patient with worsening and advanced HF
-
Part 1 | Session 3 Plenary Session 2: Managing your HF patients with comorbidities (part 1)
-
Part 1 | Session 6 Plenary Session 3: Using SGLT2 in your patients: practical considerations
-
Part 1 | Session 8 Plenary Session 4: Managing your HF patients with comorbidities (part 2)
e-SPACE Heart Failure 2022 was the third edition of the annual global online conference on heart failure. Bringing together thought-leaders from across the globe and broadcast over three time-zones – Asia, Europe, and the Americas – e-SPACE Heart Failure 2022 optimised geographical reach whilst delivering both global and regional insight.
Course leadership Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE), Dr Javed Butler (Baylor Scott and White Research Institute, Texas, US), Prof Andrew Coats (University of Warwick, Coventry, UK) and Dr Shelley Zieroth (University of Manitoba, Manitoba, CA) lead an interactive programme of plenary sessions, meet the experts, case discussions and industry sponsored sessions focusing on the patient journey.
For the first time, e-SPACE Heart Failure 2022 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.

Learning Objectives
- Review the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) as one of the leading causes of disability and mortality worldwide
- Understand the latest guideline recommendations and discuss their applicability according to patients phenotypes
- Discuss the implementation in clinical practice of the four foundational therapies and additional drugs and devices to improve patient outcomes
- Develop a comprehensive understanding of best practices for the screening, diagnosis and management of the patient with heart failure and comorbidities
- Translate the findings of recent studies and guidelines into optimal patient management in the regional contexts
Target Audience
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Faculty Biographies

Javed Butler
Professor of Medicine
Dr Javed Butler is President, Baylor Scott and White Research Institute, Senior Vice President for the Baylor Scott and White Health and Professor of Medicine at the University of Mississippi, US. He is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure.
He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.
Prof Butler has authored more than 900 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals and has been cited numerous times in America’s Best Doctors list.

Ileana L Piña
Dr Ileana L Pina is Professor at the Department of Medicine (Cardiology) and Professor in the Department of Epidemiology and Population Health at Montefiore Einstein Center for Heart and Vascular Care, US.
Dr Piña has a particular research and clinical interest in rehabilitation of heart disease in patients with heart failure. She completed a NHLBI HF ACTION trial and is in the process of examining recovery after exercise which could be translated to an additional parameter that may better predict prognosis of outcomes. In addition, there was a R21 to NHLBI to examine Vitamin D levels as another predictor from the HF ACTION database.
Dr Ileana L Pina is an Editorial Board member of Cardiac Failure Review.